Clinical trial Recruiting at 80 sites Phase 2 Interventional Ages 18 to 75

Brenipatide (LY3537031) treatment for adults with IBS‑D

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D

Run by Eli Lilly and Company · NCT07545759 · Data updated 2026-11-12

This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

More Irritable Bowel Syndrome trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment531 (estimated)
SponsorEli Lilly and Company
Industry-sponsored
Locations89 sites (Mesa, Arizona and 88 other locations)
StatusRecruiting
StartedMay 6, 2026
Main results expectedSeptember 2027
Study endsNovember 2027
Registry record updatedNovember 4, 2026
Trial IDNCT07545759 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults who meet Rome IV criteria for IBS‑D with frequent loose stools (BSFS types 6–7 on a substantial portion of bowel movements), an average worst abdominal pain score ≥3 on a 0–10 scale during screening, and no major recent diet changes are the intended participants.

Probably not a fit

People with constipation‑predominant, mixed, or unclassified IBS, those with inflammatory or immune-mediated gastrointestinal disorders, or those with known clinically significant gastric emptying abnormalities are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 study gives adults with IBS‑D subcutaneous injections of brenipatide (LY3537031) or placebo over an approximately 35‑week period to characterize safety, tolerability, side effects, and preliminary symptom effects. Participants complete a daily eDiary during screening and treatment to confirm Rome IV IBS‑D criteria and to track abdominal pain and stool form. The trial compares patient-reported outcomes between the brenipatide and placebo groups and excludes people with other IBS subtypes or inflammatory/immune‑mediated GI disorders. Dosing and follow-up visits occur at clinical sites in the United States.

Why it matters

Potential benefit: If successful, brenipatide could reduce abdominal pain and diarrhea and improve daily functioning for people with IBS‑D.

How similar studies have gone: Some other peptide- or receptor-targeting drugs for IBS‑D have shown symptom benefit in prior trials, but brenipatide (LY3537031) is a novel agent and its efficacy has not yet been established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Meet Rome IV criteria for IBS-D, which includes having greater than 25% of bowel movements with Bristol Stool Form Scale (BSFS) Types 6 or 7 and \<25% of bowel movements with BSFS Types 1 or 2
* Based on the daily eDiary collection during the screening period:

  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization
  * Have at least 4 days per week with a maximum BSFS ≥5 AND with at least 2 days of the 4 days per week with a maximum BSFS ≥6 during the 14 consecutive days prior to randomization
* Have had no major changes in diet in the 4 weeks prior to screening

Exclusion Criteria:

* Have a diagnosis of IBS with a subtype of constipation, mixed IBS, or unclassified IBS by the Rome IV criteria
* Have a history of inflammatory or immune-mediated gastrointestinal disorders
* Have a known clinically significant gastric emptying abnormality

Where it's running

  • Del Sol Research Management - Mesa
    Mesa, Arizona, United States
    Recruiting
  • Smart Cures Clinical Research
    Anaheim, California, United States
    Recruiting
  • Om Research LLC
    Lancaster, California, United States
    Recruiting
  • United Medical Doctors - Los Alamitos
    Los Alamitos, California, United States
    Recruiting
  • Encore Medical Research
    Hollywood, Florida, United States
    Recruiting
  • Clinical Research of Osceola
    Kissimmee, Florida, United States
    Recruiting
Show 44 more locations
  • Springfield Clinic - First
    Springfield, Illinois, United States
    Recruiting
  • Gastroenterology Health Partners
    New Albany, Indiana, United States
    Recruiting
  • Gastroenterology Health Partners
    Louisville, Kentucky, United States
    Recruiting
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
    Wyoming, Michigan, United States
    Recruiting
  • Ohio Gastroenterology
    Columbus, Ohio, United States
    Recruiting
  • University Gastroenterology
    Providence, Rhode Island, United States
    Recruiting
  • Biopharma Informatic, LLC
    McAllen, Texas, United States
    Recruiting
  • Southern Star Research Institute
    San Antonio, Texas, United States
    Recruiting
  • AZ Maria Middelares
    Ghent, Belgium
    Recruiting
  • AZ Sint-Lucas
    Ghent, Belgium
    Recruiting
  • UZ Leuven
    Leuven, Belgium
    Recruiting
  • Clinical Chc Montlégia
    Liège, Belgium
    Recruiting
  • AZ Delta vzw
    Roeselare, Belgium
    Recruiting
  • Bluewater Clinical Research Group Inc.
    Sarnia, Canada
    Recruiting
  • Scarborough Center for Inflammatory Bowel Disease
    Scarborough, Canada
    Recruiting
  • ClinSurge Research - LMC Scarborough / Malvern Medical Centre
    Scarborough, Canada
    Recruiting
  • Stouffville Medical Research Institute Inc.
    Stouffville, Canada
    Recruiting
  • Canadian Phase Onward
    Toronto, Canada
    Recruiting
  • Binzhou Medical University Hospital
    Binzhou, China
    Recruiting
  • Sichuan Provincial People's Hospital
    Chengdu, China
    Recruiting
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
    Recruiting
  • Zhejiang Hospital of Traditioal Chinese Medicine
    Hangzhou, China
    Recruiting
  • The Second Affiliated Hospital of University of South China
    Hengyang, China
    Recruiting
  • Huizhou Central People's Hospital
    Huizhou, China
    Recruiting
  • Huzhou Central Hospital
    Huzhou, China
    Recruiting
  • Meihekou Central Hospital
    Meihekou, China
    Recruiting
  • Quzhou People's Hospital
    Quzhou, China
    Recruiting
  • Taian City Central Hospital
    Taian, China
    Recruiting
  • Xianning Central Hospital
    Xianning, China
    Recruiting
  • Yichun People's Hospital
    Yichun, China
    Recruiting
  • FutureMeds GmbH
    Berlin, Germany
    Recruiting
  • Studienzentrum MVZ Dachau
    Dachau, Germany
    Recruiting
  • Pratia - Hamburg
    Hamburg, Germany
    Recruiting
  • Klinische Forschung Karlsruhe
    Karlsruhe, Germany
    Recruiting
  • AmBeNet GmbH
    Leipzig, Germany
    Recruiting
  • FutureMeds Offenbach
    Offenbach, Germany
    Recruiting
  • Tokyo-Eki Center-building Clinic
    Chūōku, Japan
    Recruiting
  • Sai Gastroenterology/Proctology Clinic
    Fujiidera, Japan
    Recruiting
  • Tokai University Hospital
    Isehara, Japan
    Recruiting
  • Aoyama Internal Medicine Clinic
    Kobe, Japan
    Recruiting
  • Aono Clinic
    Kobe, Japan
    Recruiting
  • Hattori Clinic - Kumamoto
    Kumamoto, Japan
    Recruiting
  • Sapporo Odori Endoscope Clinic
    Sapporo, Japan
    Recruiting
  • Nishi-Shinjuku Kisaragi Clinic
    Shinjuku-Ku, Japan
    Recruiting

+39 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.